Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-06-17 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-04-01 |
2023-12 |
-1.43 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-1.97 |
-1.31 |
0.66 |
33.50% |
2023-08-14 |
2023-06 |
-1.54 |
-1.96 |
-0.42 |
-27.27% |
2023-05-15 |
2023-03 |
-2.55 |
-2.88 |
-0.33 |
-12.94% |
2023-04-03 |
2022-12 |
-2.97 |
-2.92 |
0.05 |
1.68% |
Date |
Firm |
Action |
From |
To |
2023-07-11 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-04-06 |
Oppenheimer |
Upgrade |
|
Outperform |
2022-05-23 |
Piper Sandler |
Upgrade |
|
Overweight |
2022-05-09 |
HC Wainwright & Co. |
Upgrade |
|
Neutral |
2021-12-17 |
Oppenheimer |
Upgrade |
|
Outperform |
2021-11-18 |
HC Wainwright & Co. |
Upgrade |
|
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2021-11-30 |
AGGARWAL SUMIT |
Chief Executive Officer |
197.23K |
Conversion of Exercise of derivative security |
2021-07-29 |
BELLOFF NEIL S. |
Chief Operating Officer |
32.70K |
Conversion of Exercise of derivative security |
2021-11-28 |
GEFFKEN DANIEL E |
Chief Financial Officer |
50.00K |
Purchase |
2021-05-12 |
KARIV TOMER |
Director |
0.00 |
Purchase |
2021-11-30 |
MODUR VIJAY M.D., PH.D. |
Officer |
154.95K |
Conversion of Exercise of derivative security |
2021-05-12 |
NUSSBAUM RAN |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-03-30 |
SilverArc Capital Management, LLC |
54.08K |
420.70K |
2.50% |
2023-03-30 |
Menora Mivtachim Holdings Ltd. |
52.36K |
407.32K |
2.42% |
2023-03-30 |
American Financial Group Inc. |
37.00K |
287.86K |
1.71% |
2023-03-30 |
Harel Insurance Investments & Financial Services Ltd. |
29.41K |
228.81K |
1.36% |
2023-03-30 |
Altshuler Shaham Ltd |
25.12K |
195.46K |
1.16% |
2023-03-30 |
Vanguard Group, Inc. (The) |
20.69K |
160.94K |
0.95% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Vanguard Extended Market Index Fund |
20.64K |
160.55K |
0.95% |
2022-12-30 |
Vanguard Total Stock Market Index Fund |
16.84K |
131.01K |
0.78% |
2023-02-27 |
Fidelity Extended Market Index Fund |
8.98K |
69.90K |
0.41% |
2023-02-27 |
Fidelity NASDAQ Composite Index Fund |
2.95K |
22.98K |
0.14% |
2023-03-30 |
Fidelity NASDAQ Composite Index ETF |
2.94K |
22.90K |
0.14% |
2023-02-27 |
Fidelity Total Market Index Fund |
2.78K |
21.62K |
0.13% |
Split |
Date |
1 : 40 |
2022-12-02 |
1 : 20 |
2017-12-20 |
0.01 : 1 |
2013-10-21 |
2 : 1 |
1999-10-25 |